Breast CancerPhase 2NCT00036998
Microwave Thermotherapy in Treating Women With Stage I or Stage II Breast Cancer
A Phase 2 study testing conventional surgery, neoadjuvant therapy and thermal ablation therapy in people with Breast Cancer, run by Imunon at 8 sites in 2 countries.
Trial summary
RATIONALE: Microwave thermotherapy kills tumor cells by heating them to several degrees above body temperature. PURPOSE: Randomized phase II trial to compare the effectiveness of microwave thermotherapy before surgery to that of surgery alone in treating women who have stage I or stage II breast cancer. Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Breast Cancer
- What is being tested?
- conventional surgery, neoadjuvant therapy and thermal ablation therapy
- Type of treatment
- Surgery or procedure
- How many people
- Not given
- Where
- 8 sitesin 2 countries
- Study dates
- Aug 2001to not given
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
DISEASE CHARACTERISTICS:
- Histologically confirmed primary breast cancer by core needle biopsy
- T1a, b, c, or T2
- Diagnosis not made with a lumpectomy or incisional biopsy
- Candidate for breast conservation surgery (lumpectomy/radiotherapy)
- Tumor measurable by breast ultrasound
- No metastatic disease, including skin metastases
- No bilateral breast cancer
- No high-probability of extensive intraductal disease in situ
- No clinical fixation to the pectoralis major muscle or skin
- No involvement of the nipple
- No inflammatory breast cancer
- No multicentric disease
- Hormone receptor status:
- Not specified
PATIENT CHARACTERISTICS:
Age:
- 18 and over
Sex:
- Female
Menopausal status:
- Not specified
Performance status:
- Karnofsky 70-100%
Life expectancy:
- At least 6 months
Hematopoietic:
- Platelet count at least 100,000/mm^3 (no thrombocytopenia)
- No bleeding disorders
Hepatic:
- PT, INR, and PTT less than 1.5 times normal
- Bilirubin no greater than 2.0 mg/dL
- Transaminases no greater than 2 times normal
- No coagulopathy
- No liver disease
Renal:
- BUN less than 30 mg/dL
- Creatinine less than 1.9 mg/dL
- No renal insufficiency
Cardiovascular:
- No pacemakers or defibrillators
- No clinically significant heart disease
Other:
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use 2 forms of effective contraception, including 1 barrier method
- Able to tolerate prone position and breast compression
- No breast implants
- No prior collagen vascular disease
- No other factor or condition (other than tumor size) that would preclude lumpectomy
- No mental condition that would preclude study
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- Not specified
Chemotherapy:
- Not specified
Endocrine therapy:
- Not specified
Radiotherapy:
- See Disease Characteristics
Surgery:
- See Disease Characteristics
Other:
- No prior participation in this study
- More than 30 days since prior participation in another clinical study
- No concurrent anticoagulants
Trial locations and contacts
8 sites in 2 countries.
8 sites in 2 countries
United States7 sites
Comprehensive Breast Center of Coral Springs
Coral Springs, Florida, 33071
Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California, 90095-1781
Mroz-Baier Breast Care Center
Memphis, Tennessee, 38119
Breast Care Specialists, P.C.
Norfolk, Virginia, 23510
Oklahoma University Medical Center at University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104
St. Joseph Hospital Regional Cancer Center - Orange
Orange, California, 92868
Study site
Tacoma, Washington, 98405
United Kingdom1 site
Royal Bolton Hospital
Bolton, Lancashire, England, BL4 0JR
About this study
Official title: A Randomized Pivotal Clinical Trial In Breast Cancer Patients Of Pre-Operative Focal Microwave Thermotherapy Treatment For Early-Stage Breast Disease In Intact Breast
RATIONALE: Microwave thermotherapy kills tumor cells by heating them to several degrees above body temperature.
PURPOSE: Randomized phase II trial to compare the effectiveness of microwave thermotherapy before surgery to that of surgery alone in treating women who have stage I or stage II breast cancer.
Read the detailed description
OBJECTIVES:
- Compare the safety and efficacy of preoperative focused microwave thermotherapy followed by surgery vs surgery alone in women with early-stage primary breast cancer.
- Compare the reduction of tumor cells at surgical margins and second incision rates in women treated with these regimens.
- Compare the percentage of pathological cell death in women treated with these regimens.
- Compare the amount of surgically removed breast and tumor tissue in women treated with these regimens.
- Compare the measurement of the extent tumor margins of the surgically removed breast and tumor tissue in women treated with these regimens.
OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified according to tumor classification (T1 vs T2) and participating center. Patients are randomized to 1 of 2 treatment arms.
- Arm I:Patients undergo ultrasound-guided placement of a microwave sensor and a temperature probe (before or after compression of the breast) and external placement of 2 large opposing microwave emitters and up to 7 skin temperature sensors on the compressed breast. Patients then receive focused microwave thermotherapy that slowly heats the primary breast tumor and deep proximal breast tissue. In the absence of undue heating of the skin, a tumor temperature of 48-52° C is targeted and maintained for an equivalent thermal dose of 140-180 minutes.
Within 60 days of thermotherapy, patients undergo lumpectomy.
- Arm II: Patients undergo lumpectomy only. Patients are followed at 30 and 90 days after surgery, and then at the discretion of the physician.
PROJECTED ACCRUAL: A total of 200-222 patients (100-111 per treatment arm) will be accrued for this study.
- Conditions
- Breast Cancer
- Being tested
- conventional surgery, neoadjuvant therapy, thermal ablation therapy
- Keywords
- stage I breast cancer, stage II breast cancer
- Medical subject headings
- Breast Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
conventional surgeryProcedure or surgery
neoadjuvant therapyProcedure or surgery
thermal ablation therapyProcedure or surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Jan 2003 (estimated)
- Study startAug 2001
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Breast CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Masking
- None (open label)
Sponsor and investigators
- Lead sponsor
- Imunon
- Sponsor type
- Industry (pharma, biotech, devices)
- Investigators
- William E. Gannon, MD, Study chair, Imunon
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00036998
- Sponsor's protocol ID
- CDR0000069347
- Other IDs
- CELSION-10200202, OU-09532
- Status last verified
- Jul 2004
- First submitted
- 13 May 2002
- Last updated
- 6 Nov 2013
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 6 Nov 2013. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized Pivotal Clinical Trial In Breast Cancer Patients Of Pre-Operative Focal Microwave Thermotherapy Treatment For Early-Stage Breast Disease In Intact Breast
- ClinicalTrials.gov ID
- NCT00036998
- Acronym / sponsor ID
- CDR0000069347
- Conditions
- Breast Cancer
- Keywords
- stage I breast cancer, stage II breast cancer
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Unknown status
- Lead sponsor
- ImunonIndustry (pharma, biotech, devices)
- Study start
- Aug 2001
- First posted
- 27 Jan 2003 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
RATIONALE: Microwave thermotherapy kills tumor cells by heating them to several degrees above body temperature.
PURPOSE: Randomized phase II trial to compare the effectiveness of microwave thermotherapy before surgery to that of surgery alone in treating women who have stage I or stage II breast cancer.
Detailed description
OBJECTIVES:
- Compare the safety and efficacy of preoperative focused microwave thermotherapy followed by surgery vs surgery alone in women with early-stage primary breast cancer.
- Compare the reduction of tumor cells at surgical margins and second incision rates in women treated with these regimens.
- Compare the percentage of pathological cell death in women treated with these regimens.
- Compare the amount of surgically removed breast and tumor tissue in women treated with these regimens.
- Compare the measurement of the extent tumor margins of the surgically removed breast and tumor tissue in women treated with these regimens.
OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified according to tumor classification (T1 vs T2) and participating center. Patients are randomized to 1 of 2 treatment arms.
- Arm I:Patients undergo ultrasound-guided placement of a microwave sensor and a temperature probe (before or after compression of the breast) and external placement of 2 large opposing microwave emitters and up to 7 skin temperature sensors on the compressed breast. Patients then receive focused microwave thermotherapy that slowly heats the primary breast tumor and deep proximal breast tissue. In the absence of undue heating of the skin, a tumor temperature of 48-52° C is targeted and maintained for an equivalent thermal dose of 140-180 minutes.
Within 60 days of thermotherapy, patients undergo lumpectomy.
- Arm II: Patients undergo lumpectomy only. Patients are followed at 30 and 90 days after surgery, and then at the discretion of the physician.
PROJECTED ACCRUAL: A total of 200-222 patients (100-111 per treatment arm) will be accrued for this study.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Masking
- None (open label)
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| conventional surgery | Procedure or surgery | – |
| neoadjuvant therapy | Procedure or surgery | – |
| thermal ablation therapy | Procedure or surgery | – |
Primary outcome
Not reported in the source record.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Nov 2013.
Related trials for Breast Cancer
Active, not recruiting
Culturally-Informed Counseling in Latinas at High Risk for Hereditary Breast or Ovarian Cancer
No Evidence of Disease, BRCA1 Syndrome
Active, not recruitingPhase 3
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma
Active, not recruitingPhase 2
Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer
Recurrent Breast Carcinoma, Stage III Breast Cancer AJCC v7
Active, not recruitingPhase 2
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
RecruitingPhase 1/2
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
Pancreatic Cancer, Renal Cell Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
William E. Gannon, MD study chair
Imunon
8 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing conventional surgery, neoadjuvant therapy and thermal ablation therapy in people with Breast Cancer, run by Imunon at 8 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 6 Nov 2013. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 8 sites in United States, United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Nov 2013; AzTrials last refreshed its copy on 26 Oct 2026.